[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Dalbagni G: The management of superficial bladder cancer. Nat Clin Pract Urol; 2007 May;4(5):254-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transurethral resection should be done, but this procedure is prone to both overestimating and underestimating staging.
  • Data support the immediate postoperative instillation of a chemotherapeutic agent for patients with solitary, low-grade papillary tumors, whereas patients with multiple lesions might benefit from a more intensive adjuvant regimen.
  • Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette-Guérin has demonstrated significant benefit for tumor prophylaxis when no obvious residual disease is present.
  • Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion.
  • In this Review I present an overview of the management of nonmuscle invasive bladder cancer.
  • The most common intravesical chemotherapeutic agents are described as well as the impact of chemotherapy on the recurrence and progression of tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Transitional Cell / therapy. Cystectomy / methods. Immunotherapy / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Administration, Intravesical. BCG Vaccine / administration & dosage. Cystoscopy / methods. Female. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483810.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  • [Number-of-references] 62
  •  go-up   go-down


2. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG: Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol; 2003 Apr;7(2):112-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
  • The metastatic carcinoma can consist exclusively of the micropapillary component, which may elicit an erroneous diagnosis if located in the bladder or lung, as in the patient presented herein.
  • We present a case of a 59-year-old woman with a history of bilateral breast carcinoma status post-bilateral mastectomy, chemotherapy, and tamoxifen therapy.
  • A biopsy of the endometrium revealed a poorly differentiated carcinoma.
  • Urinary bladder biopsies showed a carcinoma with micropapillary features diagnosed as micropapillary transitional cell carcinoma.
  • Anderson Cancer Center (Houston, TX) for further treatment recommendations.
  • The mastectomy specimen showed an invasive ductal carcinoma with a significant micropapillary component.
  • In view of the morphologic and immunohistochemical profile, the carcinoma in the endometrium and urinary bladder were interpreted as metastatic lesions from the breast primary.
  • However, micropapillary serous carcinoma has a different appearance more akin to borderline tumors of the ovary.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Papillary / secondary. Endometrial Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / metabolism. Lung Neoplasms / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12715337.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


3. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL: Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer; 2007 Jul 1;110(1):62-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma.
  • The TNM stage of disease at the time of presentation was Ta in 5 patients, carcinoma in situ (CIS) in 4 patients, T1 in 35 patients, T2 in 26 patients, T3 in 7 patients, T4 in 6 patients; N+ in 9 patients, and M+ in 8 patients.
  • Bladder-sparing therapy with intravesical bacillus Calmette-Guerin therapy was attempted in 27 of 44 patients with nonmuscle-invasive disease; 67% (18 patients) developed disease progression (>or=cT2), including 22% who developed metastatic disease.
  • Of 55 patients undergoing radical cystectomy for surgically resectable disease (<or=cT4a), 23 received neoadjuvant chemotherapy and 32 were treated with initial cystectomy, with no significant difference noted in stage distribution between the 2 groups.
  • For the 23 patients treated with neoadjuvant chemotherapy, the median OS was 43.2 months with 32% of patients still alive at 5 years.
  • For the 32 patients treated with initial cystectomy, the median survival had not been reached at the time of last follow-up, with 71% still alive at 5 years.
  • Intravesical therapy appears to be ineffective in this disease and patients with surgically resectable disease should be offered early radical cystectomy.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cystectomy / methods. Female. Hospitals, University. Humans. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Retrospective Studies. Survival Analysis. Texas

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17542024.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • For the TCCs, 58.6% were superficial while 41.4% were muscle invasive, and 13.3% had nodal metastasis with distant metastasis in 8%.
  • Of the total, 5.3% were papillary urothelial tumours of low malignant potential, 33.3% pTa, 20% pT1, 10.7% pT2, 12.0% pT3 and 18.7% pT4.
  • There were ten radical cystectomies performed for transitional cell carcinomas; two had neobladder reconstruction whereas the other eight had ileal conduits.
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • Mean survival of patients with muscle invasive cancer was 33+/-5 months.
  • When compared to other studies, the incidence of muscle invasive and high-grade superficial tumours was greater.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


5. Tavora F, Epstein JI: Urothelial carcinoma with abundant myxoid stroma. Hum Pathol; 2009 Oct;40(10):1391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma with abundant myxoid stroma.
  • Thirteen cases of urothelial carcinoma with myxoid features were collected over 9 years.
  • Treatment included transurethral resection of the bladder only in 6 patients, transurethral resection of the bladder with subsequent intravesical bacillus Calmette-Guérin treatment in 4 patients, radical cystectomy only in 2 patients, and neoadjuvant chemotherapy followed by cystectomy in 1 patient.
  • In all cases, the myxoid stroma was associated with invasive urothelial carcinoma.
  • Other patterns of invasive cancer associated with myxoid stroma were short cords and individual cells.
  • The percentage of invasive urothelial carcinoma that had myxoid stroma ranged from 5% to 95% (mean, 50%).
  • An unusual finding was the presence of invasive low-grade urothelial carcinoma associated with myxoid stroma in 5 cases, 4 of which had an overlying low-grade papillary urothelial carcinoma component.
  • Urothelial carcinoma associated with the extracellular myxoid matrix was positive for MUC5 in 3 cases and for MUC2 in 2 cases.
  • The current study describes a rare variant of urothelial carcinoma that may be confused with primary or secondary adenocarcinoma of the bladder, which can have therapeutic and prognostic implications.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Cystectomy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19535127.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Izawa JI, Slaton JW, Kedar D, Karashima T, Perrotte P, Czerniak B, Grossman HB, Dinney CP: Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep; 2001 Jan-Feb;8(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.
  • It is generally accepted that there are dichotomous biologic pathways that lead to the development of either: i) superficial papillary (Ta) transitional cell carcinoma (TCC) or ii) precursor lesions to muscle-invasive (CIS, T1) TCC and muscle-invasive (> or =T2) TCC.
  • Gene expression was normalized using poly (dT) and the expression of each factor in a panel of specimens of normal urothelium.
  • VEGF, bFGF, IL-8, and MMP-9 expression was increased in muscle-invasive compared with superficial papillary tumors, (p<0.05) and VEGF expression was increased in muscle-invasive tumors compared with CIS specimens (p<0. 05).
  • bFGF, IL-8, and EGFR expression was increased in CIS specimens compared with superficial papillary tumors (p<0.05).
  • The pattern of expression of bFGF, VEGF, IL-8, MMP-9, and EGFR represent the divergent developmental pathways in the pathogenesis of bladder TCC, which characterizes superficial or invasive bladder cancer. bFGF, IL-8, and EGFR appear to be upregulated in early precursor lesions (CIS), whereas VEGF appears to be upregulated at later stages in the development of muscle-invasive TCC.
  • [MeSH-major] Carcinoma, Transitional Cell / genetics. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Colorimetry. Disease Progression. Endothelial Growth Factors / biosynthesis. Endothelial Growth Factors / genetics. Growth Substances / biosynthesis. Growth Substances / genetics. Humans. Image Processing, Computer-Assisted. In Situ Hybridization. Interleukin-8 / biosynthesis. Interleukin-8 / genetics. Lymphokines / biosynthesis. Lymphokines / genetics. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / genetics. Neoplasm Invasiveness. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Receptors, Growth Factor / biosynthesis. Receptors, Growth Factor / genetics. Staining and Labeling. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11115562.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / CA56973; United States / NCI NIH HHS / CA / CA67914
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Growth Substances; 0 / Interleukin-8; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Growth Factor; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


7. Josephson DY, Pasin E, Stein JP: Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev Anticancer Ther; 2006 Dec;6(12):1723-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Superficial 'nonmuscle-invasive' bladder tumors represent a heterogeneous group of cancers, which include those that are papillary in nature and limited to the mucosa (Ta), high grade, flat and confined to the epithelium (Tis) and those that invade the submucosa or lamina propria (T1).
  • The goal in the treatment of superficial bladder cancer is twofold: reducing tumor recurrence and the subsequent need for additional therapies, such as cystoscopy, transurethral resections, intravesical therapy and the morbidity associated with these treatments; and preventing tumor progression and the subsequent need for more aggressive therapy, such as radical cystectomy.
  • The administration of intravesical chemotherapy and immunotherapy has become an important component in accomplishing these goals.
  • [MeSH-minor] Carcinogens, Environmental / adverse effects. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / etiology. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Chromosome Aberrations. Diagnosis, Differential. Disease Progression. Hematuria / etiology. Humans. Mucous Membrane / pathology. Neoplasm Invasiveness. Neoplasm Staging. Occupational Diseases / chemically induced. Papilloma / diagnosis. Papilloma / pathology. Risk Factors. Smoking / adverse effects. Urinary Tract Infections / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181486.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental
  • [Number-of-references] 124
  •  go-up   go-down


8. Brandt WD, Matsui W, Rosenberg JE, He X, Ling S, Schaeffer EM, Berman DM: Urothelial carcinoma: stem cells on the edge. Cancer Metastasis Rev; 2009 Dec;28(3-4):291-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma: stem cells on the edge.
  • This variability likely stems from epigenetic and genetic influences, either stochastic or hardwired by cell type-specific lineage programs.
  • That differentiation underlies tumor cell heterogeneity was elegantly demonstrated in hematopoietic tumors, in which rare primitive cells (cancer stem cells (CSCs)) resembling normal hematopoietic stem cells are ultimately responsible for tumor growth and viability.
  • Because of the compelling clinical implications CSCs pose--across the entire spectrum of cancers--investigators applied the CSC model to cancers arising in tissues with crudely understood differentiation programs.
  • The recent identification of urothelial differentiation programs in urothelial carcinomas (UroCas) supports the idea that solid epithelial cancers (carcinomas) develop and differentiate analogously to normal epithelia and provides new insights about the spatial localization and molecular makeup of carcinoma CSCs.
  • Importantly, CSCs from invasive UroCas (UroCSCs) appear well situated to exchange important signals with adjacent stroma, to escape immune surveillance, and to survive cytotoxic therapy.
  • These signals have potential roles in treatment resistance and many participate in druggable cellular pathways.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 May;18(5):523-7 [18392048.001]
  • [Cites] Br J Urol. 1994 May;73(5):516-21 [8012773.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Nature. 2006 May 25;441(7092):418-9 [16724049.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Acta Haematol. 2007;117(1):8-15 [17095854.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):217-26 [17229949.001]
  • [Cites] J Clin Invest. 2007 Feb;117(2):314-25 [17256055.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1797-803 [17234707.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1097-110 [17574023.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2332-8 [17786053.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Science. 2007 Dec 14;318(5857):1722; author reply 1722 [18079385.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):190-7 [18172311.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Cell. 2008 Feb 22;132(4):598-611 [18295578.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):389-402 [18371377.001]
  • [Cites] Am J Physiol Renal Physiol. 2008 Jun;294(6):F1415-21 [18367656.001]
  • [Cites] PLoS One. 2008;3(6):e2428 [18560594.001]
  • [Cites] Cancer Invest. 2008 Aug;26(7):725-33 [18608209.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3543-53 [18948588.001]
  • [Cites] Nature. 2008 Dec 4;456(7222):593-8 [19052619.001]
  • [Cites] Int J Cancer. 2009 Jan 1;124(1):103-8 [18844223.001]
  • [Cites] Curr Opin Oncol. 2009 Jan;21(1):41-6 [19125017.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):458-68 [19174556.001]
  • [Cites] Genes Dev. 2009 Mar 15;23(6):675-80 [19261747.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):780-3 [19194462.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3364-73 [19351829.001]
  • [Cites] J Int Med Res. 2009 May-Jun;37(3):621-30 [19589244.001]
  • [Cites] Cell. 2009 Jul 23;138(2):226-8 [19632173.001]
  • [Cites] Cell. 2009 Jul 23;138(2):286-99 [19632179.001]
  • [Cites] Stem Cells. 2009 Jul;27(7):1487-95 [19544456.001]
  • [Cites] Cell. 2009 Aug 21;138(4):645-59 [19682730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21 [19666525.001]
  • [Cites] Ann N Y Acad Sci. 2009 Aug;1171:59-76 [19723038.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2095-103 [19637316.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1176:144-9 [19796242.001]
  • [Cites] Stem Cells Dev. 2009 Dec;18(10):1515-22 [19260804.001]
  • [Cites] Oncol Rep. 2000 Jan-Feb;7(1):13-6 [10601583.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1758-66 [10688835.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Jun;278(6):F867-74 [10836974.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):851-6 [10997813.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1955-9 [11395371.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] Int J Oncol. 2002 May;20(5):905-11 [11956582.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] J Urol. 2002 Aug;168(2):709-17 [12131357.001]
  • [Cites] J Pathol. 2002 Oct;198(2):245-51 [12237885.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):328-34 [12471615.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Jan 21;55(1):3-29 [12535572.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):493-504 [12875970.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):859-66 [12944571.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):465-78 [14968126.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5467-77 [15100288.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Genes Dev. 2004 Aug 1;18(15):1875-85 [15289459.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7183-90 [15492230.001]
  • [Cites] Am J Obstet Gynecol. 1969 Mar 15;103(6):810-22 [5765964.001]
  • [Cites] J Anat. 1972 Sep;112(Pt 3):433-55 [4636798.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 1):2326-9 [1277137.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Virchows Arch B Cell Pathol. 1976 Oct 1;21(4):279-98 [824809.001]
  • [Cites] Science. 1983 Jun 10;220(4602):1175-7 [6304875.001]
  • [Cites] Blood. 1990 May 15;75(10):1947-50 [2337669.001]
  • [Cites] J Biol Chem. 1990 Nov 5;265(31):19170-9 [2229070.001]
  • [Cites] Cancer Treat Res. 1991;53:335-64 [1672086.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2898-902 [8499629.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Acta Anat (Basel). 1996;155(3):163-71 [8870784.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1217-21 [9102201.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Br J Cancer. 1998;77(2):319-24 [9461004.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1090-4 [9515785.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):829-34 [9563875.001]
  • [Cites] Am J Obstet Gynecol. 1998 Apr;178(4):641-9 [9579425.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3512-7 [10416618.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):17-23 [15652746.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3790-8 [15897578.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4415-29 [15958626.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6 [15939524.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4602-8 [16034041.001]
  • [Cites] Dev Cell. 2005 Aug;9(2):173-83 [16054025.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7709-19 [16278391.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):50-4 [16330205.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):383-91 [16428476.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1554-9 [16261162.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16 [16609023.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(2):CD006018 [16625650.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • (PMID = 20012172.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA067751-13; United States / NIDDK NIH HHS / DK / R01DK072000; United States / NCI NIH HHS / CA / T32 CA067751-13; United States / NIDDK NIH HHS / DK / R01 DK072000-04; United States / NCI NIH HHS / CA / P01CA077664; United States / NIDDK NIH HHS / DK / R01 DK072000; United States / NCI NIH HHS / CA / CA077664-10; United States / NCI NIH HHS / CA / P01 CA077664-10; United States / NIDDK NIH HHS / DK / DK072000-04; United States / NCI NIH HHS / CA / P01 CA077664
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Wnt Proteins
  • [Number-of-references] 121
  • [Other-IDs] NLM/ NIHMS224847; NLM/ PMC2930269
  •  go-up   go-down


9. Izawa JI, Grossman HB: Localized bladder cancer. Curr Treat Options Oncol; 2000 Dec;1(5):423-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transitional cell carcinoma (TCC) of the bladder makes up 90% of bladder cancers.
  • Once the diagnosis of superficial TCC has been established, histologically based prognostic factors guide which therapy or combination of therapies is indicated in the management of individual patients.
  • Surgery alone (transurethral resection) is appropriate initial therapy for noninvasive papillary TCC.
  • For lamina propria invasive tumors and carcinoma in situ, intravesical immunotherapy with bacille Calmette-Guérin (BCG) is often the first line of treatment to decrease tumor recurrence and to possibly decrease progression and improve survival.
  • Intravesical chemotherapy and interferon are alternative therapies that can also decrease recurrence rates.
  • For BCG-refractory TCC, durable response rates with alternative intravesical therapies are low.
  • For superficial TCC that is refractory to endoscopic procedures and intravesical agents or for disease progression, radical cystectomy with neobladder formation or other forms of urinary diversion is the treatment of choice.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. BCG Vaccine / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Cystectomy. Diet. Endoscopy. Humans. Immunotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):137-46, [10696252.001]
  • [Cites] J Urol. 1999 Apr;161(4):1133-5; discussion 1135-6 [10081854.001]
  • [Cites] Urology. 2000 Feb;55(2):161-8 [10688071.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3603-10 [9721868.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1404-8 [7751885.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):103-13, ix [10696249.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):934-41 [7853578.001]
  • [Cites] J Urol. 1996 Sep;156(3):962-6 [8709374.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):15-24, vii-viii [10696241.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):1-13, vii [10696240.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1298-301 [9552029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1124-9 [10737480.001]
  • [Cites] J Clin Oncol. 1994 Jan;12 (1):7-13 [8270987.001]
  • [Cites] BJU Int. 2000 Mar;85(5):599-610 [10735935.001]
  • [Cites] Br J Urol. 1998 May;81(5):692-8 [9634043.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):455-65 [1636230.001]
  • [Cites] J Urol. 1998 Jun;159(6):1793-801 [9598463.001]
  • [Cites] J Urol. 1994 Jan;151(1):21-6 [8254816.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):171-8, xi [10696256.001]
  • [Cites] N Engl J Med. 1999 May 6;340(18):1390-7 [10228189.001]
  • [Cites] J Urol. 1999 Apr;161(4):1120-3 [10081851.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 21;85(14):1159-64 [8320745.001]
  • [Cites] J Urol. 1986 May;135(5):920-2 [3959241.001]
  • [Cites] Urology. 1997 Oct;50(4):529-35 [9338727.001]
  • [Cites] CA Cancer J Clin. 1998 Sep-Oct;48(5):269-84 [9742894.001]
  • [Cites] Semin Surg Oncol. 1997 Sep-Oct;13(5):291-8 [9259084.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):125-35, x [10696251.001]
  • [Cites] Eur Urol. 1995;28(4):284-90 [8575494.001]
  • [Cites] J Urol. 1999 Aug;162(2):445-50; discussion 450-1 [10411054.001]
  • [Cites] Cancer. 1999 Jun 25;87(3):118-28 [10385442.001]
  • (PMID = 12057150.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  • [Number-of-references] 34
  •  go-up   go-down


10. Kawashima A, Ujike T, Nin M, Nishimura K, Miyoshi S: [Plasmacytoid urothelial carcinoma of the bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2009 Jul;100(5):590-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasmacytoid urothelial carcinoma of the bladder: a case report].
  • We experienced a case of plasmacytoid urothelial carcinoma of the bladder.
  • Computed Tomography, Magnetic Resonance Imaging and ultra-sonography of the abdomen showed a diffuse and invasive mass occupying most of the bladder.
  • Cystoscopy showed mostly non papillary tumor in the bladder, which was resected.
  • He received radical cystectomy, and two cycles of systemic chemotherapy were performed with methotrexate, etoposide, vinblastine, and cisplatin, due to a lymphnode metastasis (pT3a, pN1, M0).
  • So, we could diagnose as plasmacytoid urothelial carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Diagnostic Imaging. Etoposide / administration & dosage. Humans. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19663248.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 13
  •  go-up   go-down


11. Cordon-Cardo C, Cote RJ, Sauter G: Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol Suppl; 2000;(205):82-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are characteristic primary abnormalities involved in th production of low-grade/well-differentiated neoplasms, which destabilize cellular proliferation but have little effect on cellula "social" interactions or differentiation, as well as the rate of cell death or apoptosis.
  • Other molecular events lead to high-grad neoplasms which disrupt growth control, including the cell cycle and apoptosis, and which have a major impact on biological behavior.
  • A primary target leading to low-grade papillary superficial bladder tumors resides on chromosome 9, while p53 gene alterations are commonly seen in flat carcinoma in situ.
  • Other molecular alterations must be elucidated, as many non-invasive neoplasms have neither chromosome 9 nor p53 alterations.
  • Novel approaches utilizing tissue microdissection techniques an molecular genetic assays are needed to shed further light on this subject.
  • Thus, clinical trials are underway to explore their use in specific situations, particularly in the surgical management of locally advanced disease, and to determine whether adjuvant chemotherapy in such patients may be of benefit.
  • The use of molecular alterations in the management of non-invasive bladder neoplasms remains to be firmly established.
  • Our knowledge of molecular alterations important in bladder cancer progression is far from complete, and further study is necessary to further elucidate cruci pathways involved in progression and therapeutic response.
  • Nevertheless, molecular alterations involving chromosome 9q and the INK4A locus in papillary superficial tumors vs changes in chromosomes 14q and 8q, p53 and RB in flat carcinoma in situ lesions may indicate a molecular basis for early events that lead to varying pathways in urothelial tumorigenesis.
  • [MeSH-major] Carcinoma in Situ / genetics. Carcinoma, Transitional Cell / genetics. Genetic Markers / genetics. Precancerous Conditions / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Progression. Humans. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11144907.001).
  • [ISSN] 0300-8886
  • [Journal-full-title] Scandinavian journal of urology and nephrology. Supplementum
  • [ISO-abbreviation] Scand J Urol Nephrol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 111
  •  go-up   go-down


12. van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA: Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol; 2006 Oct;176(4 Pt 1):1349-53; discussion 1353
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects.
  • RESULTS: One patient withdrew informed consent and refused the last treatment due to side effects.
  • Progression to invasive stage was not observed.
  • Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations.
  • Local side effects were comparable to side effects due to other chemotherapy instillations.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Aziridines / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / pathology. Indolequinones / administration & dosage. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Cohort Studies. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Urol. 2007 May;4(5):248-9 [17389884.001]
  • (PMID = 16952629.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aziridines; 0 / Indolequinones; H464ZO600O / apaziquone
  •  go-up   go-down


13. Crnolatac I, Huygens A, van Aerschot A, Busson R, Rozenski J, de Witte PA: Synthesis, in vitro cellular uptake and photo-induced antiproliferative effects of lipophilic hypericin acid derivatives. Bioorg Med Chem; 2005 Dec 1;13(23):6347-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypericin, a naturally occurring hydroxylated phenanthroperylene dione, is used as a powerful photosensitizer for photodynamic therapy as well as a diagnostic tool for the fluorescence detection of flat neoplastic lesions in the bladder of patients.
  • In vitro cellular uptake and photo-induced antiproliferative effects of the compounds were evaluated, using the human moderately differentiated non-invasive papillary transitional carcinoma RT-112 cell line.
  • [MeSH-minor] Biological Transport. Cell Line. Cell Proliferation / drug effects. Humans. Molecular Structure

  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213734.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


14. Hirayama T, Matsumoto K, Kurosaka S, Muramoto M, Irie A, Iwamura M, Baba S, Uchida T, Ichinohe M, Iwabuchi K: [A case report: small cell carcinoma transformed from transitional cell carcinoma of the urinary bladder]. Hinyokika Kiyo; 2006 Aug;52(8):633-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report: small cell carcinoma transformed from transitional cell carcinoma of the urinary bladder].
  • Cystoscopy showed a non-papillary tumor at the right side of the posterior wall.
  • Pathologic findings demonstrated superficial transitional cell carcinoma (TCC).
  • TURBT was done for the biopsy and pathologic examination showed muscle-invasive TCC.
  • After two courses of neoadjuvant chemotherapy (MVAC), we performed radical cystectomy with Hautmann's continent reservoir.
  • Pathologic findings revealed small cell carcinoma without any TCC features.
  • We report a case of primary small cell carcinoma transformed from TCC of the urinary bladder.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic. Humans. Male. Neoplasm Recurrence, Local


15. Ruoppolo M, Gozo M, Milesi R, Spina R, Fragapane G: [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ]. Urologia; 2010 Oct-Dec;77 Suppl 17:72-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
  • CIS is a flat, high-grade, non-invasive microscopic urothelial carcinoma.
  • It is considered a precursor of invasive bladder cancer.
  • CIS is classified as primary, secondary or concurrent, when occurred as isolated CIS without cuncurrent papillary tumors, or detected during the follow-up of patients with a previous papillary tumor, or finally in the presence of bladder neoplasm.
  • BCG is widely established as the treatment of choice for CIS with a success rate of approximately 70%.
  • BCG reduces the risk of progression of CIS into invasive carcinoma in 30 to 50% of cases.
  • Direct and prolonged contact between the urothelium and BCG is a prerequisite for successful therapy.
  • CIS may be present only in the epithelial lining of the prostatic urethra or in the ducts, or in the worst case it may be found in the prostatic tissue stroma.
  • 83 patients, enrolled from 1/1996 to 12/2005 at our urological department with CIS: primary (focal and multifocal) in 25, secondary in 7 and cuncurrent in 51 (associated with T1bG3 cancer in 37 cases), and urethral CIS in 5 and conservatively treated by TUR and intravescical instillations of BCG, 4 developed afterwords only invasive cancer of the urethra in the absence of bladder involvement.
  • Among the 4 patients, 3 were treated by cystoprostatourethrectomy and Platinum-based chemotherapy, 1 refused surgical treatment.
  • We conclude that prostatic/urethral involvement during follow-up after successful intravesical treatment with BCG in CIS represents a high risk of developing invasive and incontrolled cancer.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / secondary. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy / methods. Disease Progression. Female. Follow-Up Studies. Humans. Immunotherapy. Male. Neoplasm Invasiveness. Organoplatinum Compounds / administration & dosage. Prostatectomy / methods. Prostatic Neoplasms / secondary. Risk. Treatment Outcome. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308679.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Organoplatinum Compounds
  •  go-up   go-down


16. Lopez-Beltran A, Ordóñez JL, Otero AP, Blanca A, Sevillano V, Sanchez-Carbayo M, Muñoz E, Cheng L, Montironi R, de Alava E: Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch; 2010 Nov;457(5):555-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D3 gene amplification in bladder carcinoma in situ.
  • Carcinoma in situ (CIS) is a non-papillary high-grade, potentially aggressive, and unpredictable manifestation of bladder urothelial carcinoma.
  • A sequential cohort series of 28 primary (isolated) or secondary (concomitant) bladder CIS samples in which there was enough tissue material to assess Cyclin D3 gene status by fluorescent in situ hybridization was the study group.
  • Type of bladder CIS (primary vs. secondary) was unrelated to recurrence- or progression-free survival in the current series.
  • None of primary CIS cases recurred on follow-up; nine secondary CIS recurred and four of them progressed to invasive bladder carcinoma HG T1 (n = 1), T2b N0M0 (n = 1), T3b N1M0 (n = 1) and T4aN1M1 (n = 1).
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma in Situ / genetics. Carcinoma, Transitional Cell / genetics. Cyclin D3 / genetics. Gene Amplification. Gene Expression Regulation, Neoplastic. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. BCG Vaccine / therapeutic use. Blotting, Western. Disease-Free Survival. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / mortality. Proportional Hazards Models. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):95-109 [18815924.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1119-25 [12368185.001]
  • [Cites] J Urol. 1999 Mar;161(3):792-8 [10022686.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4040-8 [15173019.001]
  • [Cites] Scand J Urol Nephrol. 2004;38(4):285-90 [15669587.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):809-18 [11830537.001]
  • [Cites] Anticancer Res. 2008 Sep-Oct;28(5B):2893-900 [19031931.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):292-9 [17126995.001]
  • [Cites] Eur Urol. 2004 May;45(5):606-12 [15082203.001]
  • [Cites] J Urol. 2001 May;165(5):1488-91 [11342902.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):242-8 [15671552.001]
  • [Cites] Urology. 2003 Jun;61(6):1140-5 [12809883.001]
  • [Cites] Eur Urol. 2004 Feb;45(2):142-6 [14733997.001]
  • [Cites] Eur Urol. 2004 May;45(5):593-9 [15082201.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):90-107 [16399418.001]
  • [Cites] Int J Cancer. 2009 Nov 1;125(9):2095-103 [19637316.001]
  • [Cites] Eur Urol. 2010 Jan;57(1):12-20 [19762144.001]
  • [Cites] Urology. 2001 Jan;57(1):60-5 [11164145.001]
  • [Cites] J Pathol. 2006 May;209(1):106-13 [16482499.001]
  • [Cites] Scand J Urol Nephrol Suppl. 1994;157:147-51 [7939446.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):363-71 [15994003.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):152-60 [17011114.001]
  • [Cites] Int J Cancer. 1996 Jan 26;65(3):323-7 [8575852.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2469-74 [10357420.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jan;7(1):48-57 [19176205.001]
  • [Cites] Urol Oncol. 2009 May-Jun;27(3):258-62 [18440839.001]
  • [Cites] Eur Urol. 2006 Jul;50(1):76-82 [16413663.001]
  • (PMID = 20821231.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Biomarkers, Tumor; 0 / CCND3 protein, human; 0 / Cyclin D3
  •  go-up   go-down


17. Varol C, Thalmann GN, Burkhard FC, Studer UE: Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol; 2004 Sep;172(3):937-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution.
  • PURPOSE: With the introduction of orthotopic bladder substitution after radical cystectomy in patients with invasive bladder cancer urethral recurrences have become a therapeutic challenge.
  • Depending on the extension of recurrence and eventual concomitant metastases patients were treated with urethrectomy, no treatment, systemic chemotherapy or intraurethral bacillus Calmette-Guerin (BCG).
  • Three times the common dose of BCG (ImmuCyst, Aventis, Paris, France or OncoTICE, Organon, West Orange, New Jersey) in 150 ml NaCl 0.9% was used for intraurethral BCG perfusion therapy according to an institutional protocol using a modified Foley catheter.
  • Two patients were treated with systemic chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin) alone due to metastatic disease and 10 received intraurethral BCG therapy.
  • Five of 6 patients (83%) with carcinoma in situ remained free of recurrence following treatment with BCG, while in 4 with papillary or invasive disease treatment failed.
  • Three patients underwent urethrectomy, including 2 following failed BCG therapy for papillary disease.
  • CONCLUSIONS: Carcinoma in situ urethral recurrence following orthotopic bladder substitution can be treated successfully with intraurethral BCG perfusion therapy in approximately 80% of patients.
  • However, papillary and invasive transitional cell urethral recurrence should be treated with urethrectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Cystectomy. Urethral Neoplasms / secondary. Urethral Neoplasms / therapy. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. BCG Vaccine / administration & dosage. Humans. Male. Middle Aged. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15311003.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCG Vaccine
  •  go-up   go-down


18. Segawa N, Kotake Y, Hamada S, Takahara K, Azuma H, Katsuoka Y, Tsuji M: [Bladder cancer with skin metastasis: a case report]. Hinyokika Kiyo; 2006 Sep;52(9):711-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bladder carcinoma with skin metastasis is extremely rare.
  • Cystoscopy revealed a trigone papillary tumor.
  • Transurethral resection of bladder tumor (TURBT) was performed and the pathological diagnosis was transitional cell carcinoma (TCC), pT1, G3.
  • Thereafter, he received several courses of TURBT, intravesical chemotherapy (pirarubicin, bacillus Calmette-Guerin and mitomycin C) and intra-arterial chemotherapy because of recurrence.
  • Histological examination revealed muscle-invasive bladder cancer with a staging of T3bNOM0.
  • He received only supportive treatment during this period due to renal dysfunction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / secondary. Skin Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Administration, Intravesical. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Humans. Infusions, Intra-Arterial. Male. Methotrexate / administration & dosage. Mitomycin / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040057.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


19. Dangle PP, Wang WP, Mayerson J, Mortazavi A, Monk P: Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy. World J Surg Oncol; 2008;6:103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade papillary transitional cell carcinoma pelvic recurrence masquerading as high grade invasive carcinoma, ten years after radical cystectomy.
  • BACKGROUND: Tumor recurrence following radical cystectomy for a low-grade superficial transitional cell carcinoma (TCC) is exceedingly uncommon and has not been reported previously.
  • The pathology was consistent with a low-grade urothelial carcinoma.
  • After an unsuccessful treatment with cisplatin-based chemotherapy, the patient underwent a curative intent hemipelvectomy with complete excision of tumor and is disease free at one year follow-up.
  • CONCLUSION: A literature review related to this unusual presentation is reported and a surgical solutions over chemotherapy and radiotherapy is proposed.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Transitional Cell / pathology. Neoplasm Recurrence, Local / surgery. Pelvic Neoplasms / surgery. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - TEN.
  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Apr;165(4):1124-8; discussion 1128-30 [11257652.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2638-46 [11352955.001]
  • [Cites] Urol Int. 2001;67(1):117-8 [11464136.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2781-9 [15199091.001]
  • [Cites] Hinyokika Kiyo. 1989 Jun;35(6):1055-9 [2801393.001]
  • [Cites] J Urol. 1994 Jan;151(1):31-5; discussion 35-6 [8254828.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):1047-8 [7853557.001]
  • [Cites] Urol Int. 1998;61(2):126-7 [9873256.001]
  • [Cites] Yonsei Med J. 2005 Feb 28;46(1):181-3 [15744826.001]
  • [Cites] Jpn J Ophthalmol. 2006 Sep-Oct;50(5):469-73 [17013702.001]
  • [Cites] Hinyokika Kiyo. 2007 Mar;53(3):179-82 [17447488.001]
  • [Cites] J Urol. 2007 Dec;178(6):2308-12; discussion 2313 [17936804.001]
  • [Cites] Urology. 2009 Jan;73(1):210.e3-5 [18372021.001]
  • (PMID = 18826578.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2566572
  •  go-up   go-down


20. Dovedi SJ, Davies BR: Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev; 2009 Dec;28(3-4):355-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging targeted therapies for bladder cancer: a disease waiting for a drug.
  • Urothelial cell carcinoma is the fifth most common cancer and the costliest to treat.
  • The standard of care, intravesical chemo- and immunotherapy, while effective, is associated with a considerable side-effect profile and approximately 30% of patients either fail to respond to treatment or suffer recurrent disease within 5 years.
  • Muscle-invasive bladder cancer is life threatening, showing modest chemosensitivity, and usually requires radical cystectomy.
  • Hence, bladder cancer represents a considerable opportunity and challenge for molecularly targeted therapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Transitional Cell / drug therapy. Drug Delivery Systems. Drugs, Investigational / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Angiogenesis Inhibitors / therapeutic use. BCG Vaccine / administration & dosage. BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma in Situ / economics. Carcinoma in Situ / epidemiology. Carcinoma in Situ / immunology. Carcinoma in Situ / surgery. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / economics. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / immunology. Carcinoma, Papillary / surgery. Cell Cycle / drug effects. Clinical Trials as Topic. Combined Modality Therapy. Cyclooxygenase 2 Inhibitors / therapeutic use. Cystectomy. Disease Management. Genetic Therapy. Humans. Intercellular Signaling Peptides and Proteins. Neoplasm Invasiveness. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / physiology. Neovascularization, Pathologic / drug therapy. Signal Transduction / drug effects. Tumor Suppressor Protein p53 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997963.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / BCG Vaccine; 0 / Cyclooxygenase 2 Inhibitors; 0 / Drugs, Investigational; 0 / Intercellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 105
  •  go-up   go-down


21. Startsev VY: The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences. Arch Ital Urol Androl; 2002 Jun;74(2):54-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
  • OBJECTIVE: To determine the local control and survival of patients with bladder cancer recurrences (BCR) treated by operative methods, external beam radiotherapy (EBRT) and adjuvant chemotherapy (ACT).
  • MATERIALS AND METHODS: We have treated 180 patients (114 men, median age 64.5 years, range 56-73) with documented transitional-cell non-metastasized BC recurrences: 90 T2N0M0 and 90 T3aN0M0.
  • All patients received different operations (transurethral resection and partial cystectomies) and definitive EBRT (total dose varied from 50 to 64 Gy with a mean of 60.5 Gy, 5 days a week).
  • In a second group of patients we performed 3 courses of 4-drug regimen ACT administered with EBRT.
  • ACT consisting of cisplatin and adriamycin i.a. and methotrexate and vinblastin i.v. (M-VAC) was administered on the fourth week after radiation therapy.
  • The complete response rates in patients with clinical stage T2 and T3a disease was 64.4 and 44.4%, respectively and it was slightly higher in patients with a non-papillary cancer than in those with a papillary one.
  • CONCLUSIONS: Four-drug ACT is feasible without major toxicity and offers a potentially curative and conservative treatment for patients with localized muscle-invasive BC (bladder cancer) recurrences.
  • Bladder conservation therapy may be offered to selected patients with BC recurrences as an alternative option to radical cystectomy, and its use should be limited to teams of uro-oncologists, experienced in multi-modalty treatment.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161935.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BCG Vaccine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement